Laryngeal Carcinoma

Observed

→ investigated in trials for

Cetuximabmonoclonal antibody

20 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

16 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

14 trials (13 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinib Hydrochloridesmall molecule

13 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

10 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

9 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall molecule

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cemiplimabmonoclonal antibody

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lapatinibsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Buparlisibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Celecoxibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gefitinibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Hydroxyureasmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipatasertibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abirateronesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alvespimycinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Berzosertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Camonsertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cediranibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dasatinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Elimusertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enzalutamidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ganetespibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mitomycinsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Onalespibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Porfimer

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Romidepsinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sacituzumab Govitecanadc

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Toripalimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Laryngeal Carcinoma studied in …STUDIED_INderived10 of 172show all (up to 200)
→ studied in	NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667400Phase 1/Phase 2 · not yet recruiting Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ALIAS · 172 trials mapped (58 active)	—	—	Laryngeal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05136196Phase 2 · recruiting BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · condition mapped CURATED_BROADER · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06980038Phase 2 · recruiting Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer · condition mapped ONTOLOGY_EXACT · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04671667Phase 2 · recruiting Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05172245Phase 1 · recruiting Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer · condition mapped CURATED_BROADER · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05172258Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · condition mapped CURATED_BROADER · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02734537Phase 2 · recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery · condition mapped ONTOLOGY_EXACT · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05721755Phase 3 · active not recruiting Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck · condition mapped CURATED_BROADER · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05752149Phase 2 · recruiting Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial · condition mapped ALIAS · 172 trials mapped (58 active)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Laryngeal Carcinoma studied in …STUDIED_INderived10 of 172show all (up to 200)

→ studied in

NCT06589804Phase 3 · recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT07667400Phase 1/Phase 2 · not yet recruiting

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ALIAS · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT05136196Phase 2 · recruiting

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · condition mapped CURATED_BROADER · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT06980038Phase 2 · recruiting

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer · condition mapped ONTOLOGY_EXACT · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT04671667Phase 2 · recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT05172245Phase 1 · recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer · condition mapped CURATED_BROADER · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT05172258Phase 2 · active not recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · condition mapped CURATED_BROADER · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT02734537Phase 2 · recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery · condition mapped ONTOLOGY_EXACT · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT05721755Phase 3 · active not recruiting

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck · condition mapped CURATED_BROADER · 172 trials mapped (58 active)

—

Observed

→ studied in

NCT05752149Phase 2 · recruiting

Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial · condition mapped ALIAS · 172 trials mapped (58 active)

—

Observed